{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:09:24Z","timestamp":1791288564806,"version":"4.3.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jhep.2020.06.011","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T02:09:00Z","timestamp":1592273340000},"page":"1037-1045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-4060","authenticated-orcid":false,"given":"George V.","family":"Papatheodoridis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-8464","authenticated-orcid":false,"given":"George N.","family":"Dalekos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramazan","family":"Idilman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vana","family":"Sypsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-0672","authenticated-orcid":false,"given":"Florian","family":"Van Boemmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Calleja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spilios","family":"Manolakopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8022-8803","authenticated-orcid":false,"given":"Alessandro","family":"Loglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8581-6591","authenticated-orcid":false,"given":"Margarita","family":"Papatheodoridi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Gatselis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea","family":"Veelken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Lopez-Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4226-6400","authenticated-orcid":false,"given":"Savvoula","family":"Savvidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Kourikou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3680-8194","authenticated-orcid":false,"given":"John","family":"Vlachogiannakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostas","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5419-7158","authenticated-orcid":false,"given":"Cihan","family":"Yurdaydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2398-8392","authenticated-orcid":false,"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-7476","authenticated-orcid":false,"given":"Pietro","family":"Lampertico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.06.011_bib1","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib2","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population","volume":"66","author":"Papatheodoridis","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib4","doi-asserted-by":"crossref","first-page":"8822","DOI":"10.3748\/wjg.v19.i47.8822","article-title":"Hepatocellular carcinoma in chronic hepatitis B patients under antiviral therapy","volume":"19","author":"Vlachogiannakos","year":"2013","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.06.011_bib5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib6","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jhep.2015.05.019","article-title":"Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection?","volume":"63","author":"Wong","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs. tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2020.06.011_bib8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A\u00a0multicenter study of entecavir vs. tenofovir on prognosis of treatment-naive chronic hepatitis B in South Korea","volume":"71","author":"Kim","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib9","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/gutjnl-2019-318947","article-title":"Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naive patients with chronic hepatitis B in Korea: a large scale, propensity score analysis","volume":"69","author":"Lee","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2020.06.011_bib10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.06.011_bib12","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.06.011_bib13","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib14","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","article-title":"EASL-EORTC Clinical Practice Guidelines: management of hepatocellular carcinoma","volume":"56","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.06.011_bib15","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/jvh.12971","article-title":"Mortality, liver transplantation and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs. tenofovir","volume":"25","author":"Kim","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.06.011_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.06.011_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.14309\/ajg.0000000000000428","article-title":"Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B","volume":"115","author":"Hsu","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2020.06.011_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","article-title":"The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jhep.2020.06.011_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl18546","article-title":"Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2020","journal-title":"Gut Liver"},{"issue":"Suppl","key":"10.1016\/j.jhep.2020.06.011_bib20","first-page":"129A","article-title":"Tenofovir versus entecavir in HBV chronic infection: impact on HCC and other liver-related complications occurrences","volume":"70","author":"Pol","year":"2019","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2020.06.011_bib21","first-page":"302A","article-title":"Risk of incident hepatocellular carcinoma in hepatitis B-infected patients treated with tenofovir disoproxil fumarate versus entecavir: a US administrative claims analysis","volume":"70","author":"Kim","year":"2019","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2020.06.011_bib22","first-page":"313A","article-title":"Tenofovir reduce risk of hepatocellular carcinoma development higher than entecavir in chronic B hepatitis patients with liver cirrhosis","volume":"70","author":"Chang","year":"2019","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2020.06.011_bib23","first-page":"578A","article-title":"Occurrence of hepatocellular carcinoma in chronic hepatitis B patients undergoing entecavir or tenofovir treatment","volume":"70","author":"Lee","year":"2019","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2020.06.011_bib24","first-page":"291A","article-title":"A\u00a0systematic review and network meta-analysis comparing the effects of nucleos(t)ide analogues on the incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"70","author":"Dave","year":"2019","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2020.06.011_bib25","first-page":"307A","article-title":"Tenofovir compared to entecavir on risk of\u00a0hepatocellular carcinoma in patients with chronic hepatitis B: a\u00a0systematic review and meta-analysis","volume":"70","author":"Choi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.06.011_bib26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1053\/j.gastro.2019.11.007","article-title":"Is tenofovir superior to entecavir in reducing the risk of hepatocellular carcinoma in chronic hepatitis B? The controversy continues","volume":"158","author":"Lampertico","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.06.011_bib27","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/jvh.12358","article-title":"Long-term entecavir or tenofovir disoproxil fumarate therapy in treatment-naive chronic hepatitis B patients in the real-world setting","volume":"22","author":"Idilman","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2020.06.011_bib28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/liv.13450","article-title":"Validation of PAGE-B model in Asian chronic hepatitis B patients receiving entecavir or tenofovir","volume":"37","author":"Kim","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.06.011_bib29","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1007\/s10620-017-4448-7","article-title":"Effectiveness and safety of entecavir or tenofovir in a Spanish cohort of chronic hepatitis B patients: validation of the page-B score to predict hepatocellular carcinoma","volume":"62","author":"Riveiro-Barciela","year":"2017","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2020.06.011_bib30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/hepr.13194","article-title":"Remaining hepatocellular carcinoma risk in chronic hepatitis B patients receiving entecavir\/tenofovir in South Korea","volume":"48","author":"Yu","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2020.06.011_bib31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","article-title":"Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study","volume":"381","author":"Marcellin","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.06.011_bib32","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hep.23785","article-title":"Long-term entecavir therapy results in the reversal of fibrosis\/cirrhosis and continued histological improvement in patients with chronic hepatitis B","volume":"52","author":"Chang","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl","key":"10.1016\/j.jhep.2020.06.011_bib33","first-page":"11A","article-title":"Prediction and need for surveillance of hepatocellular carcinoma (HCC) development after the first 5 years of entecavir (ETV) or tenofovir disoproxil fumarate (TDF) therapy in Caucasian chronic hepatitis B (CHB) patients of the PAGE-B cohort","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"Hepatology"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820303822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820303822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T17:44:54Z","timestamp":1764611094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820303822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0168827820303822"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.06.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}